Clinical Trial Update: TATE and Pembrolizumab (MK3475) in mCRC and NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Teclison's TATE in combination with pembrolizumab (MK3475) for metastatic colorectal cancer and non-small cell lung cancer; recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Teclison Ltd. | Conditions: Colorectal Cancer; Lung Cancer | Phase 2 | Status: RECRUITING